The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 15, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 15.
Number 5: The United Kingdom’s Medicines and Healthcare Products Regulatory Agency announced that it will not make any sudden changes to the nation’s regulatory framework following Brexit.
Number 4: A newly published study found that pediatric patients with Crohn disease who received early combination therapy with infliximab and azathioprine had significantly increased linear growth compared with patients who received step-up therapy.
Number 3: Several European nations are amending their policies in order to create better conditions for biosimilar uptake.
Number 2: Sandoz announced that the FDA has accepted its Biologics License Application for a proposed adalimumab biosimilar.
Number 1: The Medicare Payment Advisory Commission called for changes to Medicare Part D to remove financial disincentives that block the use of lower-cost biosimilar therapies.
Finally, last week, our e-newsletter asked whether you think that Congress should revisit legislative solutions to the problem of high drug prices. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.